title: Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy.
abstract: BACKGROUND
  Capsule endoscopy (CE) of the small bowel has become a standard diagnostic tool, but there have been concerns regarding the risk of capsule retention in certain high-risk groups. The Agile patency system, an ingestible and dissolvable capsule with an external scanner, was developed to allow physicians to perform CE with greater confidence that the capsule will be safely excreted in patients at risk for capsule retention.
  
  
  OBJECTIVE
  Our purpose was to assess the ability of the device to help physicians identify which patients with known strictures may safely undergo CE.
  
  
  METHODS
  Patients with known strictures ingested the new patency capsule and underwent periodic scanning until it was excreted. The intestinal tract was considered to be sufficiently patent if the capsule was excreted intact or if the capsule was not detected by the scanner at 30 hours after ingestion. If patency was established, then standard CE was performed.
  
  
  METHODS
  International multicenter study.
  
  
  METHODS
  A total of 106 patients with known strictures.
  
  
  METHODS
  Agile patency system.
  
  
  METHODS
  Performance and safety of Agile patency system.
  
  
  RESULTS
  A total of 106 patients ingested the patency capsule. Fifty-nine (56%) excreted it intact and subsequently underwent CE. There were no cases of capsule retention. Significant findings on CE were found in 24 (41%). There were 3 severe adverse events.
  
  
  CONCLUSIONS
  These results suggest that the Agile patency system is a useful tool for physicians to use before CE in patients with strictures to avoid retention. This group of patients may have a high yield of clinically significant findings at CE. This capsule may determine whether patients who have a contraindication to CE may safely undergo CE and obtain useful diagnostic information.
authors: Hospital Virgen de la Macarena, Seville, Spain.
authors: Juan M
authors: JM
authors: Herrerias
authors: Jonathan A
authors: JA
authors: Leighton
authors: Guido
authors: G
authors: Costamagna
authors: Anthony
authors: A
authors: Infantolino
authors: Rami
authors: R
authors: Eliakim
authors: Doron
authors: D
authors: Fischer
authors: David T
authors: DT
authors: Rubin
authors: Howard D
authors: HD
authors: Manten
authors: Eitan
authors: E
authors: Scapa
authors: Douglas R
authors: DR
authors: Morgan
authors: Ari J
authors: AJ
authors: Bergwerk
authors: Binyamin
authors: B
authors: Koslowsky
authors: Samuel N
authors: SN
authors: Adler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D053705:Capsule Endoscopes / Q000009:adverse effects*; D053704:Capsule Endoscopy / Q000009:adverse effects*; D002214:Capsules / Q000592:standards*; D004867:Equipment Design; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000517:prevention & control*; D007421:Intestine, Small; D008297:Male; D008403:Mass Screening / Q000295:instrumentation; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D002214:Capsules